Genomic biomarkers offer great potential for diagnostics and new forms of treatment, such as immunotherapy.
Miniaturised lab-on-a-chip approaches are prime candidates for developing viable diagnostic tests and instruments because they are small, need only limited test volumes and can be cost-effective.
A team of scientists and engineers from the University of California, Santa Cruz and Brigham Young University in the US have developed just such an approach capable of processing biomolecular samples from blood.
Laboratory-on-a-chip describes the miniaturisation of laboratory functions such as blood testing on a chip.
Instead of transferring relatively large (micro- to millilitres) samples between test tubes or using bulky analytical equipment, samples and reagents are handled on chip-scale devices with fluidic microchannels.
This requires much smaller test volumes, and multiple functions can be integrated on a single device, improving speed, reliability and portability of these lab processes.
"Our approach uses optofluidic chips where both fluid processing and optical sensing are done on a chip, allowing for further miniaturisation and performance enhancements of the chip system," said Holger Schmidt, professor at the University of California, Santa Cruz.
The next step to realising the potential of this research is to move towards real clinical samples and to detect individual DNA biomarkers.
"We have shown single nucleic acid analysis in the context of on-chip Ebola detection and would like to transfer that to this application," said Schmidt.
Other goals for the team include increasing the speed of the analysis process, and integrating more optical elements on the chip.
This research is expected to have a wide range of applications because the underlying principle of this kind of on-chip optical analysis and manipulation is very general.
"In the near term, we hope to build new diagnostic instruments for molecular diagnostics with applications in oncology and infectious disease detection, both viruses and (drug-resistant) bacteria," Schmidt said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
